DISCLOSURE: This site receives compensation from featured companies, which may influence rankings. Read Advertising Disclosure
Ozempic (Semaglutide for Diabetes)
brandedFDA-approved for type 2 diabetes. NOT approved for weight loss (off-label use only).
Est. Cost
$199-$349
/month
Ozempic is the most recognized GLP-1 brand name, FDA-approved for type 2 diabetes management. While not FDA-approved for weight loss specifically, it is frequently prescribed off-label for that purpose. It contains semaglutide, the same active ingredient as Wegovy, but at a lower maximum dose (2mg vs 2.4mg). In 2026, Novo Nordisk introduced a self-pay offer starting at $199/month for the first two fills.
Dosage Format
Weekly subcutaneous injection — 0.25mg, 0.5mg, 1mg, or 2mg
Type
Branded
Best For
Patients with type 2 diabetes who also want to manage weight
Key Benefit
Same active ingredient as Wegovy but lower max dose (2mg vs 2.4mg) and different FDA indication
Where to Get Ozempic (Semaglutide for Diabetes)
Compare providers offering ozempic (semaglutide for diabetes) — ranked by our editorial team
Ro
Available through Novo Nordisk self-pay program; $199/mo intro for first two fills
$199-$349/mo
/month
How Ozempic (Semaglutide for Diabetes) Works
Ozempic works as a GLP-1 receptor agonist, mimicking the GLP-1 hormone to regulate blood sugar levels, slow gastric emptying, and reduce appetite. It activates receptors in the brain that help control hunger and food intake. While its primary FDA approval is for blood sugar management in type 2 diabetes, these appetite-reducing effects have made it widely used off-label for weight management.
Side Effects
Common
- • Nausea (especially during dose titration)
- • Diarrhea
- • Vomiting
- • Constipation
- • Abdominal pain
- • Injection site reactions
Serious (Rare)
- • Pancreatitis (rare)
- • Gallbladder problems
- • Thyroid tumors (risk seen in animal studies)
- • Kidney injury from dehydration due to GI side effects
Who Is Eligible
Ozempic is FDA-approved for adults with type 2 diabetes. For off-label weight loss use, providers may prescribe it based on clinical judgment, though insurance typically will not cover it for weight loss. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use Ozempic.